Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 1

Conditions

Leukemia, Myeloid, Acute 5Glioblastoma 4Breast Neoplasms 4Melanoma 3Pathologic Complete Response 2Ovarian Neoplasms 2Neoplasms 2Multiple Myeloma 2Lung Neoplasms 2Gliosarcoma 2Colorectal Neoplasms 2Carcinoma, Renal Cell 2Carcinoma, Non-Small-Cell Lung 2Wilms Tumor 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumor 1Smoldering Multiple Myeloma 1Small Cell Lung Carcinoma 1Prostatic Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasm Metastasis 1Myelodysplastic Syndromes 1Lymphoma, Follicular 1Glioma 1Breast Neoplasms, Male 1Brain Neoplasms 1Advanced Ovarian Cancer 1Advanced Cancer 1

Interventions

sargramostim 2Monatide (IMS 3015) 2Granulocyte-Macrophage Colony-Stimulating Factor 2Azacitidine 2venetoclax 1ruxolitinib 1rucaparib 1olaparib 1cc-486 1Pemetrexed 1Observation 1Nivolumab 1Decitabine 1Cytarabine 1Bortezomib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Pathologic Complete Response × sargramostim × Clear all
NCT04229979 2025-10-01

REGAL

Sellas Life Sciences Group

Phase 3 Active not recruiting
127 enrolled
Other hematologic neoplasm

Pathologic Complete Response, Leukemia, Myeloid, Acute

NCT01266083 2024-11-19

WT1 Vaccine Treatment of Patients in Remission From Acute Myeloid Leukemia (AML) or Acute Lymphoblastic Leukemia (ALL)

Sellas Life Sciences Group

Phase 2 Completed
22 enrolled 8 charts
LymphoidOther hematologic neoplasm

Pathologic Complete Response, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡